Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Hanefeld

Showing results (161-170 of 224) with videos related to

Pageof 23
Sort By:
Diabetologia|May 20, 1999
Is the newly suggested fasting plasma glucose cut-off point for the diagnosis of diabetes the right one?C Koehler, T Temelkova-Kurktschiev, E Henkel, et al.
Biochimica Et Biophysica Acta|January 3, 1995
Very fast ultracentrifugation of serum lipoproteins: influence on lipoprotein separation and compositionJ Pietzsch, S Subat, S Nitzsche, et al.
Zentralblatt Fur Allgemeine Pathologie U. Pathologische Anatomie|January 1, 1973
[Morphological changes in the liver of chronic alcoholics without internal diseases and their diagnostic evaluation (author's transl)]H Stötzner, W Jarobb, K U Schentke, et al.
Deutsche Zeitschrift Fur Verdauungs- Und Stoffwechselkrankheiten|January 1, 1973
[Activation analysis of human tissue samples: manganese, copper, and zinc in the liver]W Leonhardt, S Niese, W Jarobb, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|January 1, 1997
Anomalies of lipoprotein pattern and fibrinolysis in acromegalic patients: relation to growth hormone levels and insulin-like growth factor IJ Wildbrett, M Hanefeld, K Fücker, et al.
The Clinical Investigator|July 1, 1994
Impact of hormone replacement therapy on postprandial lipoproteins and lipoprotein(a) in normolipidemic postmenopausal womenU Julius, H Fritsch, W Fritsch, et al.
Diabetologia|May 28, 2004
Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial dataJ-L Chiasson, R G Josse, R Gomis, et al.
Diabetes Care|October 17, 1998
The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes MellitusJ L Chiasson, R Gomis, M Hanefeld, et al.
Diabetes Care|August 1, 1991
Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet aloneM Hanefeld, S Fischer, J Schulze, et al.
Diabetes Care|December 29, 2000
Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c levelT S Temelkova-Kurktschiev, C Koehler, E Henkel, et al.
Pageof 23

Showing results (161-170 of 224) with videos related to

Sort By:
Pageof 23
Diabetologia|May 20, 1999
Is the newly suggested fasting plasma glucose cut-off point for the diagnosis of diabetes the right one?C Koehler, T Temelkova-Kurktschiev, E Henkel, et al.
Biochimica Et Biophysica Acta|January 3, 1995
Very fast ultracentrifugation of serum lipoproteins: influence on lipoprotein separation and compositionJ Pietzsch, S Subat, S Nitzsche, et al.
Zentralblatt Fur Allgemeine Pathologie U. Pathologische Anatomie|January 1, 1973
[Morphological changes in the liver of chronic alcoholics without internal diseases and their diagnostic evaluation (author's transl)]H Stötzner, W Jarobb, K U Schentke, et al.
Deutsche Zeitschrift Fur Verdauungs- Und Stoffwechselkrankheiten|January 1, 1973
[Activation analysis of human tissue samples: manganese, copper, and zinc in the liver]W Leonhardt, S Niese, W Jarobb, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|January 1, 1997
Anomalies of lipoprotein pattern and fibrinolysis in acromegalic patients: relation to growth hormone levels and insulin-like growth factor IJ Wildbrett, M Hanefeld, K Fücker, et al.
The Clinical Investigator|July 1, 1994
Impact of hormone replacement therapy on postprandial lipoproteins and lipoprotein(a) in normolipidemic postmenopausal womenU Julius, H Fritsch, W Fritsch, et al.
Diabetologia|May 28, 2004
Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial dataJ-L Chiasson, R G Josse, R Gomis, et al.
Diabetes Care|October 17, 1998
The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes MellitusJ L Chiasson, R Gomis, M Hanefeld, et al.
Diabetes Care|August 1, 1991
Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet aloneM Hanefeld, S Fischer, J Schulze, et al.
Diabetes Care|December 29, 2000
Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c levelT S Temelkova-Kurktschiev, C Koehler, E Henkel, et al.
Pageof 23